To determine the relative roles of T-cells and NK cells and evaluate cytokine/chemokine levels over time during anti-CD137/IL-2-Fc therapy, we depleted CD8+ T-cells or NK cells from C57Bl/6 mice bearing B16F10 tumors, then began systemic anti-CD137/IL2-Fc therapy on day 8 after tumor inoculation (Supplementary Fig. 3a). Here, TNFRSF9 is linked to neoplasm.